Hepatocyte growth factor therapy - Kringle Pharma/ChronTech Pharma

Drug Profile

Hepatocyte growth factor therapy - Kringle Pharma/ChronTech Pharma

Alternative Names: ChronSeal

Latest Information Update: 18 Jun 2014

Price : $50

At a glance

  • Originator Kringle Pharma; Tripep
  • Developer ChronTech Pharma; Kringle Pharma
  • Class Antifibrotics; Growth factors; Neuropsychotherapeutics
  • Mechanism of Action Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Leg ulcer

Most Recent Events

  • 18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Norway (Topical)
  • 18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Sweden (Topical)
  • 21 Apr 2011 Clinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top